Cargando…
Systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer
In the United States alone one in five newly diagnosed cancers in men are prostate carcinomas (PCa). Androgen receptor (AR) status and the PI3K-AKT-mTOR signal transduction pathway are critical in PCa. After initial response to single drugs targeting these pathways resistance often emerges, indicati...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026592/ https://www.ncbi.nlm.nih.gov/pubmed/29977602 http://dx.doi.org/10.1038/s41540-018-0064-1 |
_version_ | 1783336463103950848 |
---|---|
author | Ebhardt, H. Alexander Root, Alex Liu, Yansheng Gauthier, Nicholas Paul Sander, Chris Aebersold, Ruedi |
author_facet | Ebhardt, H. Alexander Root, Alex Liu, Yansheng Gauthier, Nicholas Paul Sander, Chris Aebersold, Ruedi |
author_sort | Ebhardt, H. Alexander |
collection | PubMed |
description | In the United States alone one in five newly diagnosed cancers in men are prostate carcinomas (PCa). Androgen receptor (AR) status and the PI3K-AKT-mTOR signal transduction pathway are critical in PCa. After initial response to single drugs targeting these pathways resistance often emerges, indicating the need for combination therapy. Here, we address the question of efficacy of drug combinations and development of resistance mechanisms to targeted therapy by a systems pharmacology approach. We combine targeted perturbation with detailed observation of the molecular response by mass spectrometry. We hypothesize that the molecular short-term (24 h) response reveals details of how PCa cells adapt to counter the anti-proliferative drug effect. With focus on six drugs currently used in PCa treatment or targeting the PI3K-AKT-mTOR signal transduction pathway, we perturbed the LNCaP clone FGC cell line by a total of 21 treatment conditions using single and paired drug combinations. The molecular response was analyzed by the mass spectrometric quantification of 52 proteins. Analysis of the data revealed a pattern of strong responders, i.e., proteins that were consistently downregulated or upregulated across many of the perturbation conditions. The downregulated proteins, HN1, PAK1, and SPAG5, are potential early indicators of drug efficacy and point to previously less well-characterized response pathways in PCa cells. Some of the upregulated proteins such as 14-3-3 proteins and KLK2 may be useful early markers of adaptive response and indicate potential resistance pathways targetable as part of combination therapy to overcome drug resistance. The potential of 14-3-3ζ (YWHAZ) as a target is underscored by the independent observation, based on cancer genomics of surgical specimens, that its DNA copy number and transcript levels tend to increase with PCa disease progression. The combination of systematic drug perturbation combined with detailed observation of short-term molecular response using mass spectrometry is a potentially powerful tool to discover response markers and anti-resistance targets. |
format | Online Article Text |
id | pubmed-6026592 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-60265922018-07-05 Systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer Ebhardt, H. Alexander Root, Alex Liu, Yansheng Gauthier, Nicholas Paul Sander, Chris Aebersold, Ruedi NPJ Syst Biol Appl Review Article In the United States alone one in five newly diagnosed cancers in men are prostate carcinomas (PCa). Androgen receptor (AR) status and the PI3K-AKT-mTOR signal transduction pathway are critical in PCa. After initial response to single drugs targeting these pathways resistance often emerges, indicating the need for combination therapy. Here, we address the question of efficacy of drug combinations and development of resistance mechanisms to targeted therapy by a systems pharmacology approach. We combine targeted perturbation with detailed observation of the molecular response by mass spectrometry. We hypothesize that the molecular short-term (24 h) response reveals details of how PCa cells adapt to counter the anti-proliferative drug effect. With focus on six drugs currently used in PCa treatment or targeting the PI3K-AKT-mTOR signal transduction pathway, we perturbed the LNCaP clone FGC cell line by a total of 21 treatment conditions using single and paired drug combinations. The molecular response was analyzed by the mass spectrometric quantification of 52 proteins. Analysis of the data revealed a pattern of strong responders, i.e., proteins that were consistently downregulated or upregulated across many of the perturbation conditions. The downregulated proteins, HN1, PAK1, and SPAG5, are potential early indicators of drug efficacy and point to previously less well-characterized response pathways in PCa cells. Some of the upregulated proteins such as 14-3-3 proteins and KLK2 may be useful early markers of adaptive response and indicate potential resistance pathways targetable as part of combination therapy to overcome drug resistance. The potential of 14-3-3ζ (YWHAZ) as a target is underscored by the independent observation, based on cancer genomics of surgical specimens, that its DNA copy number and transcript levels tend to increase with PCa disease progression. The combination of systematic drug perturbation combined with detailed observation of short-term molecular response using mass spectrometry is a potentially powerful tool to discover response markers and anti-resistance targets. Nature Publishing Group UK 2018-07-02 /pmc/articles/PMC6026592/ /pubmed/29977602 http://dx.doi.org/10.1038/s41540-018-0064-1 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Review Article Ebhardt, H. Alexander Root, Alex Liu, Yansheng Gauthier, Nicholas Paul Sander, Chris Aebersold, Ruedi Systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer |
title | Systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer |
title_full | Systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer |
title_fullStr | Systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer |
title_full_unstemmed | Systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer |
title_short | Systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer |
title_sort | systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026592/ https://www.ncbi.nlm.nih.gov/pubmed/29977602 http://dx.doi.org/10.1038/s41540-018-0064-1 |
work_keys_str_mv | AT ebhardthalexander systemspharmacologyusingmassspectrometryidentifiescriticalresponsenodesinprostatecancer AT rootalex systemspharmacologyusingmassspectrometryidentifiescriticalresponsenodesinprostatecancer AT liuyansheng systemspharmacologyusingmassspectrometryidentifiescriticalresponsenodesinprostatecancer AT gauthiernicholaspaul systemspharmacologyusingmassspectrometryidentifiescriticalresponsenodesinprostatecancer AT sanderchris systemspharmacologyusingmassspectrometryidentifiescriticalresponsenodesinprostatecancer AT aebersoldruedi systemspharmacologyusingmassspectrometryidentifiescriticalresponsenodesinprostatecancer |